Contrarius Investment Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Contrarius Investment Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-216,211	Closed	-$495K	–	66
2017 Q3	$495K	Hold	216,211	–	–	0.03%	59
2017 Q2	$292K	Hold	216,211	–	–	0.02%	53
2017 Q1	$463K	Sell	216,211 -18,963	-8%	-$71.3K	0.03%	52
2016 Q4	$1.04M	Sell	235,174 -21,957	-9%	-$104K	0.08%	47
2016 Q3	$1.25M	Sell	257,131 -41,424	-14%	-$189K	0.09%	53
2016 Q2	$985K	Sell	298,555 -111,201	-27%	-$420K	0.08%	53
2016 Q1	$1.46M	Buy	+409,756	New	+$2.11M	0.13%	46

Other funds holding ARLZ

PCM

PAR Capital Management Boston, Massachusetts $4.03B AUM 35.05% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BMCM

Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.29B AUM 26.05% 1-Year Est. Return

Contrarius Investment Management's ARLZ Position: Q4 2017 in Review

Contrarius Investment Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q4 2017, closing a stake of 216,211 shares — an estimated $495K sold.

Contrarius Investment Management first reported a position in ARLZ in Q1 2016 and held it in 7 quarters. The position peaked at $1.46M in Q1 2016. 63 funds tracked by Wall St. Rank hold ARLZ as of Q4 2017.

Contrarius Investment Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
Contrarius Investment Management sold 216,211 Aralez Pharmaceuticals Inc. shares in Q4 2017, an estimated $495K.
Contrarius Investment Management first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 7 quarters.
Contrarius Investment Management's Aralez Pharmaceuticals Inc. position peaked at $1.46M in Q1 2016.
63 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q4 2017.

Based on Contrarius Investment Management's 13F filing for Q4 2017, filed 9 Feb 2018.